Could a daily pastille help fight recurrent brain tumors?
Disease control
Recruiting now
This pilot study tests whether adding APG-157 (a pastille dissolved in the mouth) to standard bevacizumab can help people with recurrent high-grade glioma. About 30 participants will take APG-157 three times daily while continuing bevacizumab. The study tracks survival, tumor res…
Phase: PHASE1, PHASE2 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC